Acomplia (Rimonabant) is now available!

We are proud to announce that 4Rx are now able to offer Acomplia from our website.

Acomplia has been keenly awaited, as it promises a new hope for many people who have had little or no luck with other diets or treatments.

It is the only endocannabinoid receptor antagonist in clinical development and thus offers a unique therapeutic approach to appetite control and weight reduction.

The drug also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body’s response to tobacco dependence.

Cincinnati, OH, March 9, 2004 - C Researchers at the University of Cincinnati College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared with placebo, markedly reduced post-cessation weight gain at 10 weeks, and was well-tolerated.

Acomplia / Rimonabant - Technical Information

Acomplia was recently approved in the UK as a controlled medication and is under application in the US. The active ingredient in Acomplia is rimonabant, which is a CB1 endocannabinoid receptor antagonist.
(The endocannabinoid system is in the part of the brain that regulates metabolism, energy levels and appetite).

Accomplia product has, since June 2006, been authorized for the European Market